Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback